Resources for the healthcare professional
Resources for your patients
Pfizer is committed to ensuring patients are satisfied with their IBRANCE® + endocrine therapy (ET) and that they achieve the full benefits this treatment option can offer them. For this reason, we have created a series of patient-centred materials to help them understand both their metastatic breast cancer (mBC) disease and why IBRANCE® is appropriate for them.
“Your guide to treatment with IBRANCE®” is a short but comprehensive booklet containing clear and patient friendly explanations of what IBRANCE® is and how it works, how it should be taken and monitored, and possible side effects that may occur, together with tips on how to manage these. It also includes a side effects diary to track how the patient is doing on their IBRANCE® therapy, and a complete blood count (CBC) reminder card to help them keep track of their scheduled blood tests.
To help patients ensure they are taking their IBRANCE® therapy correctly, there is also a dosing tracker available to help them keep track of when to take their medication. There is a dosing tracker for both IBRANCE® + letrozole and IBRANCE® + fulvestrant.
Please contact your local IBRANCE® representative for copies of your guide to treatment with IBRANCE® for your patients.
- IBRANCE® Summary of Product Characteristics.
Date of preparation: March 2020
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.